Hospital
ST James Healthcare
ST James Healthcare was paid $1.70M by Medicaid between Jan 2018 and Dec 2024, across 255 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoST JAMES HEALTHCARE
BUTTE, MT 59701
BUTTE, MT 59701
33aNPI1528037215assigned 03/15/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.70M
24GClaims569,437
24DCodes billed255
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Montana
Rank by total paid#4 of 10
Median peer was paid$774K
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PALAGI, PAM controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,061 | $222K | |
| 2019 | 69,377 | $261K | |
| 2020 | 67,729 | $207K | |
| 2021 | 88,372 | $253K | |
| 2022 | 98,557 | $281K | |
| 2023 | 103,086 | $227K | |
| 2024incomplete | 67,255 | $254K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 27,811 | 24,179 | $490K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 14,608 | 12,672 | $180K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 3,670 | 3,171 | $69K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 4,609 | 4,037 | $63K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 3,096 | 2,834 | $59K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.2% | 1,041 | 979 | $54K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 3,161 | 2,941 | $49K |
| G0378 | Hospital observation service, per hour | 2.8% | 3,982 | 2,115 | $47K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,569 | 1,451 | $32K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 6,337 | 5,143 | $25K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 1,063 | 963 | $24K |
| 80053 | Comprehensive metabolic panel | 1.3% | 28,058 | 23,065 | $23K |
243 more codes
| J3490 | Unclassified drugs | 1.3% | 42,237 | $23K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 4,165 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 10,293 | $19K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 1,675 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 34,660 | $18K |
| 87081 | 1.0% | 4,568 | $18K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,665 | $17K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,319 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,647 | $16K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,357 | $16K |
| 87070 | <1% | 3,782 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,082 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,256 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,128 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,614 | $11K |
| 81001 | <1% | 13,582 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,618 | $10K |
| 87088 | <1% | 3,232 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,053 | $9K |
| 73610 | <1% | 942 | $9K | |
| 74018 | <1% | 613 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,597 | $9K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,668 | $8K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,212 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,201 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,650 | $8K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,486 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 511 | $7K |
| 86140 | <1% | 3,850 | $7K | |
| 73562 | <1% | 1,256 | $6K | |
| 87186 | <1% | 3,242 | $6K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 157 | $6K |
| 87400 | <1% | 484 | $6K | |
| 73130 | <1% | 916 | $6K | |
| 87631 | <1% | 428 | $6K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 704 | $6K |
| 73110 | <1% | 521 | $5K | |
| 12001 | <1% | 355 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,119 | $5K |
| 84703 | <1% | 3,975 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,372 | $5K |
| 83605 | <1% | 8,265 | $5K | |
| 80061 | Lipid panel | <1% | 3,096 | $4K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 108 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,075 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 832 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,032 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,259 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,820 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,003 | $4K |
| 84439 | <1% | 1,759 | $4K | |
| 83690 | <1% | 6,178 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 607 | $4K |
| 73630 | <1% | 977 | $3K | |
| 73030 | <1% | 795 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 899 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,498 | $3K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 1,146 | $3K |
| 87040 | <1% | 3,019 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 985 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 780 | $3K |
| C1769 | Guide wire | <1% | 554 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,852 | $3K |
| 0352U | <1% | 514 | $3K | |
| 81025 | <1% | 2,821 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,231 | $2K |
| 90715 | <1% | 518 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 446 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,869 | $2K |
| 93325 | <1% | 82 | $2K | |
| 87660 | <1% | 1,398 | $2K | |
| 87510 | <1% | 1,398 | $2K | |
| 82805 | <1% | 935 | $2K | |
| 87480 | <1% | 1,398 | $2K | |
| 87806 | <1% | 1,263 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,859 | $2K |
| 96376 | <1% | 2,015 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,660 | $2K |
| 84145 | <1% | 867 | $1K | |
| 74019 | <1% | 207 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,278 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 842 | $1K |
| 83655 | <1% | 369 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 498 | $1K |
| 86900 | <1% | 2,479 | $1K | |
| 70486 | <1% | 59 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 193 | $1K |
| 87077 | <1% | 1,312 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,703 | $1K |
| 84484 | <1% | 6,438 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,958 | $1K |
| 86850 | <1% | 2,441 | $1K | |
| 85379 | <1% | 3,102 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,519 | $1K |
| 83735 | <1% | 4,018 | $1K | |
| 82728 | <1% | 592 | $976.41 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,845 | $970.05 |
| 73502 | <1% | 234 | $947.89 | |
| 86901 | <1% | 2,527 | $869.80 | |
| 86780 | <1% | 1,341 | $848.50 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,095 | $816.11 |
| 85652 | <1% | 807 | $799.98 | |
| 87205 | <1% | 2,210 | $783.28 | |
| 85027 | <1% | 1,367 | $776.55 | |
| 12011 | <1% | 14 | $771.83 | |
| 83540 | <1% | 736 | $752.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,346 | $752.10 |
| 93971 | <1% | 299 | $730.11 | |
| 84702 | <1% | 884 | $702.28 | |
| 82565 | <1% | 866 | $689.50 | |
| 84481 | <1% | 244 | $629.65 | |
| 83880 | <1% | 2,244 | $622.95 | |
| 85610 | <1% | 4,202 | $620.61 | |
| 87340 | <1% | 1,074 | $606.41 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,126 | $584.04 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 700 | $583.17 |
| 83550 | <1% | 636 | $500.41 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 278 | $455.17 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,828 | $438.84 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,624 | $435.83 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 510 | $415.58 |
| 85651 | <1% | 252 | $392.04 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 904 | $362.78 |
| 82607 | <1% | 458 | $359.44 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,502 | $356.91 |
| 82570 | <1% | 517 | $309.12 | |
| 82947 | <1% | 2,176 | $295.78 | |
| 82803 | <1% | 216 | $293.22 | |
| 85018 | <1% | 239 | $288.02 | |
| 97161 | <1% | 499 | $280.87 | |
| 85014 | <1% | 185 | $270.61 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 76 | $258.92 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,170 | $254.07 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,747 | $236.75 |
| 72100 | <1% | 280 | $234.04 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,155 | $220.35 |
| 85730 | <1% | 881 | $205.89 | |
| 77065 | Tomosynthesis, mammo | <1% | 84 | $205.75 |
| 86003 | <1% | 25 | $191.35 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 347 | $180.83 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $175.94 |
| 82962 | <1% | 2,044 | $173.25 | |
| 73140 | <1% | 65 | $155.34 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,632 | $149.26 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,556 | $134.75 |
| 87075 | <1% | 256 | $119.93 | |
| 87430 | <1% | 24 | $114.32 | |
| 80178 | <1% | 15 | $112.78 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,889 | $111.14 |
| 86803 | <1% | 252 | $98.13 | |
| 86762 | <1% | 206 | $97.47 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 125 | $90.26 |
| 96367 | <1% | 429 | $88.35 | |
| 97035 | <1% | 387 | $80.96 | |
| 82550 | <1% | 60 | $75.60 | |
| 86038 | <1% | 26 | $74.18 | |
| 93017 | <1% | 158 | $73.51 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 427 | $70.79 |
| 81003 | <1% | 13 | $67.22 | |
| 80076 | <1% | 91 | $56.88 | |
| 84156 | <1% | 105 | $47.51 | |
| 84100 | <1% | 908 | $32.99 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 864 | $32.50 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 123 | $29.75 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 531 | $25.50 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 609 | $15.17 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 350 | $9.52 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 94 | $5.43 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 176 | $2.13 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 15 | $1.72 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 783 | $0.33 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 1,696 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 826 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 94 | $0.00 |
| 73080 | 0% | 26 | $0.00 | |
| 99152 | 0% | 145 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 345 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 36 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 97 | $0.00 |
| 71271 | 0% | 65 | $0.00 | |
| 72131 | 0% | 12 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 40 | $0.00 |
| 84550 | 0% | 26 | $0.00 | |
| 72110 | 0% | 119 | $0.00 | |
| 76642 | 0% | 103 | $0.00 | |
| 70030 | 0% | 27 | $0.00 | |
| 82140 | 0% | 118 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 71 | $0.00 |
| 82248 | 0% | 31 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 42 | $0.00 |
| 94729 | 0% | 12 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 24 | $0.00 |
| 94726 | 0% | 12 | $0.00 | |
| 29125 | 0% | 14 | $0.00 | |
| 85007 | 0% | 26 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 58 | $0.00 |
| 84146 | 0% | 14 | $0.00 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 30 | $0.00 |
| 84403 | 0% | 15 | $0.00 | |
| 83516 | 0% | 16 | $0.00 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 52 | $0.00 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 0% | 14 | $0.00 |
| 76770 | 0% | 13 | $0.00 | |
| 72050 | 0% | 17 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,255 | $0.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 688 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,286 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 210 | $0.00 |
| 88142 | 0% | 1,249 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,692 | $0.00 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 66 | $0.00 |
| 88304 | 0% | 45 | $0.00 | |
| 80050 | General health panel | 0% | 2,447 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 95 | $0.00 |
| 71101 | 0% | 82 | $0.00 | |
| 82746 | 0% | 14 | $0.00 | |
| 82043 | 0% | 142 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 18 | $0.00 |
| 82950 | 0% | 79 | $0.00 | |
| 94762 | 0% | 36 | $0.00 | |
| 15271 | 0% | 16 | $0.00 | |
| 97165 | 0% | 49 | $0.00 | |
| 87449 | 0% | 44 | $0.00 | |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 92 | $0.00 |
| 70496 | 0% | 13 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| 99234 | 0% | 205 | $0.00 | |
| 87486 | 0% | 29 | $0.00 | |
| 64493 | 0% | 25 | $0.00 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 32 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 24 | $0.00 |
| 64483 | 0% | 64 | $0.00 | |
| 86706 | 0% | 13 | $0.00 | |
| 86364 | 0% | 12 | $0.00 | |
| 97597 | 0% | 32 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 12 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 20 | $0.00 |
| 83001 | 0% | 14 | $0.00 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 13 | $0.00 |
| 82150 | 0% | 14 | $0.00 | |
| 87581 | 0% | 29 | $0.00 | |
| 72072 | 0% | 12 | $0.00 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPALAGI, PAM (VP FINANCE)
Parent organizationSISTERS OF CHARITY OF LEAVENWORTH HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| SCL Health Montana | Billings, MT | $2.70M |
| SCL Health Montana | Billings, MT | $865K |
| SCL Health Montana | Billings, MT | $448K |
| SCL Health Montana | Billings, MT | $387K |
| ST. James Healthcare | Butte, MT | $314K |
| SCL Health Montana | Billings, MT | $43K |
| SCL Health Montana | Billings, MT | $29K |
| ST. James Healthcare | Boulder, MT | $22K |
| SCL Health Montana | Billings, MT | $15K |
| SCL Health Montana | Billings, MT | $11K |
| SCL Health Montana | Billings, MT | $7K |
| SCL Health Montana | Billings, MT | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.